Free Trial

Iovance Biotherapeutics (IOVA) Stock Price, News & Analysis

-0.26 (-2.80%)
(As of 02:58 PM ET)
Today's Range
50-Day Range
52-Week Range
4.51 million shs
Average Volume
7.86 million shs
Market Capitalization
$2.52 billion
P/E Ratio
Dividend Yield
Price Target

Iovance Biotherapeutics MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
171.0% Upside
$24.64 Price Target
Short Interest
22.90% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.62mentions of Iovance Biotherapeutics in the last 14 days
Based on 13 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($1.37) to ($0.97) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.89 out of 5 stars

Medical Sector

219th out of 930 stocks

Biological Products, Except Diagnostic Industry

26th out of 153 stocks

IOVA stock logo

About Iovance Biotherapeutics Stock (NASDAQ:IOVA)

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

IOVA Stock Price History

IOVA Stock News Headlines

Piper Sandler Keeps Their Buy Rating on Iovance Biotherapeutics (IOVA)
Why Iovance Stock Is Down 18% Today
See More Headlines
Receive IOVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
10 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$1.19 million
Book Value
$2.43 per share


Free Float
Market Cap
$2.60 billion

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Frederick G. Vogt Esq. (Age 50)
    J.D., Ph.D., Interim CEO, President, General Counsel & Corporate Secretary
    Comp: $1.39M
  • Mr. Jean-Marc Bellemin M.B.A. (Age 51)
    CFO, Principal Accounting Officer & Treasurer
    Comp: $932.2k
  • Dr. Igor P. Bilinsky (Age 51)
    Chief Operating Officer
    Comp: $932.2k
  • Dr. Friedrich Graf Finckenstein M.D. (Age 57)
    Chief Medical Officer
    Comp: $1.06M
  • Ms. Sara Pellegrino
    Vice President of Investor Relations & Public Relations
  • Ms. Tracy Winton
    Senior Vice President of Human Resources
  • Mr. Howard B. Johnson M.B.A. (Age 64)
    Chief Business Officer
  • Mr. James Ziegler M.B.A.
    Executive Vice President of Commercial
  • Dr. Raj K. Puri M.D.
    Ph.D., Executive VP of Regulatory Strategy & Translational Medicine
  • Mr. Brian Shew M.B.A.
    Senior VP & Head of Digital and Information Technology

IOVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Iovance Biotherapeutics stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IOVA shares.
View IOVA analyst ratings
or view top-rated stocks.

What is Iovance Biotherapeutics' stock price target for 2024?

10 Wall Street research analysts have issued 1-year target prices for Iovance Biotherapeutics' stock. Their IOVA share price targets range from $17.00 to $34.00. On average, they anticipate the company's stock price to reach $24.64 in the next twelve months. This suggests a possible upside of 171.0% from the stock's current price.
View analysts price targets for IOVA
or view top-rated stocks among Wall Street analysts.

How have IOVA shares performed in 2024?

Iovance Biotherapeutics' stock was trading at $8.13 at the beginning of the year. Since then, IOVA stock has increased by 11.8% and is now trading at $9.09.
View the best growth stocks for 2024 here

When is Iovance Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our IOVA earnings forecast

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) issued its quarterly earnings results on Thursday, May, 9th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.03. The biotechnology company had revenue of $0.72 million for the quarter, compared to analysts' expectations of $1.99 million. Iovance Biotherapeutics had a negative trailing twelve-month return on equity of 71.45% and a negative net margin of 23,615.70%. The firm's revenue was up 71400.0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.50) EPS.

What ETFs hold Iovance Biotherapeutics' stock?
What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), Xtrackers California Municipal Bond ETF (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX).

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.90%), Avoro Capital Advisors LLC (4.18%), Price T Rowe Associates Inc. MD (1.88%), Hood River Capital Management LLC (0.94%), Principal Financial Group Inc. (0.72%) and Rice Hall James & Associates LLC (0.61%). Insiders that own company stock include Frederick G Vogt, Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum.
View institutional ownership trends

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IOVA) was last updated on 5/30/2024 by Staff

From Our Partners